Seeking Alpha
 

Arena Pharmaceuticals, Inc. (ARNA)

- NASDAQ
  • Jun. 11, 2014, 6:18 PM
    • During a CNBC Fast Money appearance, Arena (ARNA) CEO Jack Lief was tight-lipped about rumors Belviq partner Eisai (ESALY) is interested in acquiring his company.
    • Investors trying to read between the lines see reasons to be hopeful.
    • Lief also mentioned Belviq prescriptions are seeing week/week growth.
    | 13 Comments
  • Jul. 9, 2012, 10:56 AM
    Arena Pharmaceuticals (ARNA +4.3%) rallies with the help of a Sunday Bloomberg column discussing potential M&A interest in the drug developer, thanks to recent FDA approval of its Belviq weight-loss drug. Analysts speculate GlaxoSmithKline (currently divesting a diet pill line) or Japan's Eisai (the U.S. launch partner for Belviq) could make a bid. 25.3% of Arena's float was shorted as of June 15.
    | 6 Comments
Visit Seeking Alpha's
ARNA vs. ETF Alternatives
Company Description
Arena Pharmaceuticals, Inc., is a biopharmaceutical company engaged on discovering, developing and commercializing drugs that target G protein-coupled receptors to address unmet medical needs.
Sector: Healthcare
Industry: Biotechnology
Country: United States